ClinicalTrials.gg
RecruitingNCT07360353FURSUpdated Jan 27, 2026

Comparison Between Different Types of Flexible Ureteroscopes

An interventional study of LithoVue™ (Boston Scientific Corporation) and WiScope® (OTU Medical Inc. (Silicon Valley, USA)) in Renal Calculi and Nephrolithiasis, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Kidney Calculi by Ain Shams University — 6 open to participants now, 7 under way, none of them phase 3. Kidney Calculi · Ain Shams University.

Planned enrollment
2nd of 14
180 · median 128
Started
2026
with 2 others
No phase
13 of 14
6 open now
Registered
12th of 14
by date

Among the 14 studies in Kidney Calculi by Ain Shams University, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2026, is one of 13 with no phase, and was the 12th registered.

Kidney Calculi

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

Browse Kidney Calculi studies →

Open to participants now

6 of the 14 studies in Kidney Calculi by Ain Shams University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Kidney Calculi by Ain Shams University, or all of them as a file.
02

Study summary

The current study aims to compare the performance of three distinct single-use digital flexible ureteroscope types in terms of cost-effectiveness, postoperative complications, operating time, and stone-free rates (SFRs).

Read the detailed description

Retrograde intrarenal surgery (RIRS) is the preferred treatment modality for renal stones measuring less than 20 millimeters (mm). Several types of flexible ureteroscopes are currently available on the market from different manufacturers. However, there is a shortage of comparative studies evaluating the performance of different single-use flexible ureteroscopes.

This study aims to compare the performance of three different single-use digital flexible ureteroscopes in terms of cost-effectiveness, postoperative complications, operative time, and stone-free rates (SFRs).

03

Conditions studied

  • Renal Calculi
  • Nephrolithiasis

Keywords

  • Flexible ureteroscopy
  • Single-use flexible ureteroscope
  • Renal stones
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 to 60 years.
  • Presence of renal stones measuring less than 20 millimeters (mm).

Exclusion criteria

Exclusion Criteria:

  • Renal stones larger than 20 millimeters (mm).
  • Uncontrolled bleeding disorders or coagulopathies.
  • Active urinary tract infection.
  • Renal failure.
  • Uncontrolled diabetes mellitus, hypertension, or hepatic dysfunction.
  • Pregnancy.
  • Abnormal urinary tract anatomy or known ureteric stricture.
  • History of previous open ureteric surgery.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    LithoVue™ (Boston Scientific Corporation)

    Participants randomized to this arm will undergo retrograde intrarenal surgery (RIRS) for renal stone management using the LithoVue™ single-use digital flexible ureteroscope.

    Device: LithoVue™ (Boston Scientific Corporation)

  • Active comparator
    WiScope® (OTU Medical Inc. (Silicon Valley, USA))

    Participants randomized to this arm will undergo retrograde intrarenal surgery (RIRS) for renal stone management using the WiScope® single-use digital flexible ureteroscope.

    Device: WiScope® (OTU Medical Inc. (Silicon Valley, USA))

  • Active comparator
    Single-Use Ureterorenoscope (Scivita Medical Technology Co., Ltd.)

    Participants randomized to this arm will undergo retrograde intrarenal surgery (RIRS) for renal stone management using the single-use digital flexible ureterorenoscope manufactured by Scivita Medical Technology Co., Ltd.

    Device: Single-Use Ureterorenoscope (Scivita Medical Technology Co., Ltd.)

Interventions

  • DeviceLithoVue™ (Boston Scientific Corporation)

    Participants randomized to this arm will undergo retrograde intrarenal surgery (RIRS) for renal stone management using the LithoVue™ single-use digital flexible ureteroscope.

  • DeviceWiScope® (OTU Medical Inc. (Silicon Valley, USA))

    Participants randomized to this arm will undergo retrograde intrarenal surgery (RIRS) for renal stone management using the WiScope single-use digital flexible ureteroscope.

  • DeviceSingle-Use Ureterorenoscope (Scivita Medical Technology Co., Ltd.)

    Participants randomized to this arm will undergo retrograde intrarenal surgery (RIRS) for renal stone management using the single-use digital flexible ureterorenoscope manufactured by Scivita Medical Technology Co., Ltd.

06

What researchers measure

Primary outcomes

  1. Cost-effectiveness of single-use flexible ureteroscopes

    Comparison of total procedural cost and stone-free rate among three single-use flexible ureteroscopes used in retrograde intrarenal surgery (RIRS).

    Time frame: 4 weeks postoperatively

Secondary outcomes

  1. Operative Time and Postoperative Complications

    Incidence of postoperative complications within the postoperative period.

    Time frame: up to 4 weeks postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2026, 6 months after the start.

Of 183 non-industry interventional studies with no phase under Kidney Calculi, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 6 months is below that.

Counting every sponsor, half of 199 studies reached it within 26 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2026
First posted
Jan 22, 2026
StartActual
Jan 25, 2026
Primary completionEst.
Aug 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07360353
Responsible party
Hesham Elsayed Mohammed (Principal Investigator, Ain Shams University) — Principal investigator
First posted
Jan 22, 2026
Start date
Jan 25, 2026
Primary completion
Aug 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Jan 27, 2026

Study contacts

Hesham E Khayrallah, Resident
Contact
heshamkhayrallah111@gmail.com
+201016704043
Ashraf M Satour, Lecturer
Contact
+201050505463
Hesham E Khayrallah, Resident
principal investigator · Ain Shams University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion